Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of FAM13A gene transcripts in evaluating clinical prognosis of glioblastoma patients

A glioblastoma, FAM13A-004 technology, applied in the field of medicine, can solve problems such as poor treatment effect, achieve the effect of optimizing treatment plan and improving overall survival

Pending Publication Date: 2021-12-31
HARBIN MEDICAL UNIVERSITY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The treatment of glioblastoma is mainly based on surgical resection, combined with multiple treatments such as radiotherapy and chemotherapy, but the treatment effect is not good

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of FAM13A gene transcripts in evaluating clinical prognosis of glioblastoma patients
  • Application of FAM13A gene transcripts in evaluating clinical prognosis of glioblastoma patients
  • Application of FAM13A gene transcripts in evaluating clinical prognosis of glioblastoma patients

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1 RBMX expression level to evaluate glioblastoma subtype and prognosis

[0042] 1. Screening the transcriptional regulators related to the prognosis of glioblastoma through the database

[0043] The GBM transcriptome typing system of TCGA (The Cancer Genome Atlas) is currently the most commonly used typing system, which includes the preneural type (Proneural) and the mesenchymal type (Mesenchymal). The two subtypes are closely related and often involve EMT progress in GBM. In the present invention, through the subtype annotation of more than 1,000 GBM samples from the TCGA database and the GSE16011 database, 404 transcription factor gene expression differences were screened between Proneural GBM and Mesenchymal GBM, and then combined with TCGA-U133A, Agilent, HiSeq and GSE16011 multi-platform results and clinical prognosis data found that RBMX was lowly expressed in Mesenchymal GBM and highly expressed in Proneural GBM, and the survival time of glioblastoma pat...

Embodiment 2

[0067] Example 2 Correlation detection between RBMX expression and EMT markers

[0068] RBMX is low expressed in Mesenchymal glioblastoma and highly expressed in Proneural glioblastoma. RBMX, as a transcription factor, is involved in the process of EMT. The expressions of EMT-related markers E-cadherin, Claudin1, N-cadherin, Slug and β-catenin in knockdown and overexpression RBMX cell lines were detected by Western blot (WB), immunofluorescence and immunohistochemistry .

[0069] 1. Immunofluorescence technique

[0070] (1) Divide 5×10 3 Spread the cells evenly on the cell slides of the 24-well plate overnight to ensure the adherent growth of the cells;

[0071] (2) Fix the cells with 4% paraformaldehyde, permeate the membrane with PBS solution containing 0.5% Triton, and seal the cell slide with 5% fetal bovine serum (BSA);

[0072] (3) Add E-cadherin, Claudin1, N-cadherin, Slug and β-catenin specific antibodies (primary antibodies) to the cell slides, add 200 μL to each...

Embodiment 3

[0087] Example 3 Using qPCR technology and agarose gel electrophoresis technology to detect the expression levels of transcripts FAM13A-004 and FAM13A-001

[0088] RBMX-encoded RNA-binding proteins play diverse regulatory roles in pre- and post-transcriptional processes, and are involved in tissue-specific regulation of gene transcription and selective transcription of pre-mRNAs. By analyzing the TCGA transcript sequencing data, we found that the expression of RBMX was correlated with the expression level of more than 7000 transcripts (r>0.3 or Figure 4 a. The FAM13A-004 transcript contains a RAS homologous GTPase-activating protein (RhoGAP, Ras homologous GTPase-activating protein) domain, which affects GTPase activity, down-regulates the RhoA signaling pathway, inhibits the progression of EMT, and inhibits the malignant proliferation of GBM. The FAM13A-001 transcript contains two coiled coil domains (CCDs), which are involved in protein-protein interactions. By binding to t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of FAM13A gene transcripts in evaluating clinical prognosis of glioblastoma patients. According to the application, a glioblastoma cell line is detected, the RBMX expression level is found to be related to the clinical prognosis of the glioblastoma patients, and the expression of two FAM13A-004 and FAM13A-001 transcripts encoded by the FAM13A gene is found to be related to the RBMX expression level and the clinical prognosis. The FAM13A-004 and FAM13A-001 transcripts can be used for evaluating the clinical prognosis of the glioblastoma patients. The application provides an effective technical means for guiding individualized treatment of the glioblastoma patients and optimizing a treatment scheme to achieve the maximum treatment benefit, the overall lifetime of the glioblastoma patients is prolonged, and the progress of the accurate treatment scheme of glioblastoma is promoted.

Description

technical field [0001] The invention relates to the application of the FAM13A gene transcript in evaluating the clinical prognosis of glioblastoma patients. In particular, it involves the application of two transcripts FAM13A-004 and FAM13A-001 of the FAM13A gene in evaluating the clinical prognosis of glioblastoma patients. The invention belongs to the technical field of medicine. Background technique [0002] Glioblastoma (GBM) is one of the most common tumors of the central nervous system, which is highly aggressive, highly malignant, and has a poor prognosis. The treatment of glioblastoma is mainly based on surgical resection, combined with various treatment methods such as radiotherapy and chemotherapy, but the treatment effect is not good. Glioblastoma is a tumor originating from the neuroepithelium. Different types of glioblastoma have great differences in histopathological morphology, invasion and progression, and clinical prognosis. Glioblastoma subtypes are inte...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886C12Q1/686C12Q1/6841C12N15/11
CPCC12Q1/6886C12Q1/686C12Q1/6841C12Q2600/106C12Q2600/118C12Q2600/158C12Q2521/107C12Q2543/10
Inventor 蔡金全孟祥祺蒋传路齐腾飞
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com